NCCTG (Alliance) N0572: A phase II trial of sorafenib and temsirolimus in recurrent glioblastoma (GBM) patients who progress following prior RT/temozolomide (TMZ) and VEGF inhibitors (VEGFi)
- Citation:
- J Clin Oncol vol 31 (15 suppl) abstr 2014
- Meeting Instance:
- ASCO 2013
- Year:
- 2013
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 2773
- Pharmas:
- Grants:
- Corr. Author:
- Authors:
- K. Jaeckle D. Schiff S. Anderson E. Galanis P. Stella P. Flynn J. Sarkaria C. Giannini B. Erickson J. Buckner
- Networks:
- Study
- NCCTG-N0572
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 1/2
- Keywords: